Search Results

There are 18056 results for: content related to: HLA-B*5801: utility and cost-effectiveness in the A sia- P acific R egion

  1. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

    Internal Medicine Journal

    Volume 42, Issue 4, April 2012, Pages: 411–416, M. H. Lee, S. L. Stocker, J. Anderson, E. J. Phillips, D. Nolan, K. M. Williams, G. G. Graham, J. R. Sullivan and R. O. Day

    Version of Record online : 13 APR 2012, DOI: 10.1111/j.1445-5994.2011.02567.x

  2. You have free access to this content
    Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing

    Clinical Pharmacology & Therapeutics

    Volume 93, Issue 2, February 2013, Pages: 153–158, M S Hershfield, J T Callaghan, W Tassaneeyakul, T Mushiroda, C F Thorn, T E Klein and M T M Lee

    Version of Record online : 17 OCT 2012, DOI: 10.1038/clpt.2012.209

  3. You have full text access to this Open Access content
    Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method

    Clinical and Translational Science

    Volume 8, Issue 6, December 2015, Pages: 834–836, Lin Cheng, Lihua Zhang, Lichen Gao, Wei Zhang, Xiaoping Chen and Hong-Hao Zhou

    Version of Record online : 14 DEC 2015, DOI: 10.1111/cts.12365

  4. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong

    British Journal of Dermatology

    Volume 167, Issue 1, July 2012, Pages: 44–49, M.L.S. Chiu, M. Hu, M.H.L. Ng, C.K. Yeung, J.C-Y. Chan, M.M. Chang, S.H. Cheng, L. Li and B. Tomlinson

    Version of Record online : 8 MAY 2012, DOI: 10.1111/j.1365-2133.2012.10894.x

  5. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity

    Tissue Antigens

    Volume 78, Issue 1, July 2011, Pages: 11–20, L. Kostenko, L. Kjer-Nielsen, I. Nicholson, F. Hudson, A. Lucas, B. Foley, K. Chen, K. Lynch, J. Nguyen, A. H. B. Wu, B. D. Tait, R. Holdsworth, S. Mallal, J. Rossjohn, M. Bharadwaj and J. McCluskey

    Version of Record online : 19 APR 2011, DOI: 10.1111/j.1399-0039.2011.01649.x

  6. Pharmacogenetics of Allopurinol—Making an Old Drug Safer

    The Journal of Clinical Pharmacology

    Volume 53, Issue 7, July 2013, Pages: 675–679, May P. S. Lam, Chi K. Yeung and Bernard M. Y. Cheung

    Version of Record online : 4 FEB 2013, DOI: 10.1002/jcph.67

  7. You have free access to this content
    2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

    Arthritis Care & Research

    Volume 64, Issue 10, October 2012, Pages: 1431–1446, Dinesh Khanna, John D. Fitzgerald, Puja P. Khanna, Sangmee Bae, Manjit K. Singh, Tuhina Neogi, Michael H. Pillinger, Joan Merill, Susan Lee, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, Fernando Perez-Ruiz, Will Taylor, Frédéric Lioté, Hyon Choi, Jasvinder A. Singh, Nicola Dalbeth, Sanford Kaplan, Vandana Niyyar, Danielle Jones, Steven A. Yarows, Blake Roessler, Gail Kerr, Charles King, Gerald Levy, Daniel E. Furst, N. Lawrence Edwards, Brian Mandell, H. Ralph Schumacher, Mark Robbins, Neil Wenger and Robert Terkeltaub

    Version of Record online : 28 SEP 2012, DOI: 10.1002/acr.21772

  8. You have free access to this content
    Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study

    Arthritis Care & Research

    Volume 65, Issue 4, April 2013, Pages: 578–584, Seoyoung C. Kim, Craig Newcomb, David Margolis, Jason Roy and Sean Hennessy

    Version of Record online : 28 MAR 2013, DOI: 10.1002/acr.21817

  9. You have free access to this content
    Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol

    Arthritis & Rheumatism

    Volume 64, Issue 8, August 2012, Pages: 2529–2536, Lisa K. Stamp, William J. Taylor, Peter B. Jones, Jo L. Dockerty, Jill Drake, Christopher Frampton and Nicola Dalbeth

    Version of Record online : 27 JUL 2012, DOI: 10.1002/art.34488

  10. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case–control clinical study

    British Journal of Dermatology

    Volume 173, Issue 2, August 2015, Pages: 555–558, L. Cheng, Y. Xiong, C.Z. Qin, W. Zhang, X.P. Chen, J. Li and H.H. Zhou

    Version of Record online : 22 JUN 2015, DOI: 10.1111/bjd.13688

  11. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response

    Clinical & Experimental Allergy

    Volume 43, Issue 11, November 2013, Pages: 1246–1255, J. Yun, J. Mattsson, K. Schnyder, S. Fontana, C. R. Largiadèr, W. J. Pichler and D. Yerly

    Version of Record online : 24 OCT 2013, DOI: 10.1111/cea.12184

  12. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department – Cagliari University (Italy)

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue 11, November 2012, Pages: 1424–1430, L. Atzori, A.L. Pinna, L. Mantovani, C. Ferreli, M. Pau, M. Mulargia and N. Aste

    Version of Record online : 24 OCT 2011, DOI: 10.1111/j.1468-3083.2011.04313.x

  13. You have free access to this content
    HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens–Johnson syndrome/toxic epidermal necrolysis in a Portuguese population

    British Journal of Dermatology

    Volume 169, Issue 3, September 2013, Pages: 660–665, M. Gonçalo, I. Coutinho, V. Teixeira, A.R. Gameiro, M.M. Brites, R. Nunes and A. Martinho

    Version of Record online : 30 AUG 2013, DOI: 10.1111/bjd.12389

  14. A study of HLA class I and class II 4-digit allele level in Stevens–Johnson syndrome and toxic epidermal necrolysis

    International Journal of Immunogenetics

    Volume 38, Issue 4, August 2011, Pages: 303–309, A. F. Cristallo, J. Schroeder, A. Citterio, G. Santori, G. M. Ferrioli, U. Rossi, G. Bertani, S. Cassano, P. Gottardi, N. Ceschini, F. Barocci, G. Ribizzi, V. Cutrupi, R. Cairoli, V. Rapisarda, E. A. Pastorello and S. Barocci

    Version of Record online : 4 MAY 2011, DOI: 10.1111/j.1744-313X.2011.01011.x

  15. You have free access to this content
    Rules of engagement: turning recommendations into results in the diagnosis and management of gout

    International Journal of Rheumatic Diseases

    Volume 18, Issue 3, March 2015, Pages: 261–263, Rebecca Grainger and Andrew A. Harrison

    Version of Record online : 29 APR 2015, DOI: 10.1111/1756-185X.12665

  16. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia

    International Journal of Dermatology

    Volume 49, Issue 7, July 2010, Pages: 834–841, Wen Yi Ding, Chew Kek Lee and Siew Eng Choon

    Version of Record online : 21 JUN 2010, DOI: 10.1111/j.1365-4632.2010.04481.x

  17. You have free access to this content
    Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA

    Allergy

    Volume 67, Issue 11, November 2012, Pages: 1338–1346, J. Yun, J. Adam, D. Yerly and W. J. Pichler

    Version of Record online : 3 SEP 2012, DOI: 10.1111/all.12008

  18. You have free access to this content
    Pharmacogenetics of cutaneous adverse drug reactions

    The Journal of Dermatology

    Volume 38, Issue 3, March 2011, Pages: 246–254, Michiko AIHARA

    Version of Record online : 22 FEB 2011, DOI: 10.1111/j.1346-8138.2010.01196.x

  19. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia

    International Journal of Rheumatic Diseases

    Volume 18, Issue 6, July 2015, Pages: 669–678, Shaoyong Xu, Xiangyang Liu, Jie Ming, Shenren Chen, Yangang Wang, Xiumei Liu, Hong Liu, Yongde Peng, Jianqin Wang, Jinying Lin, Haiwang Ji, Bin Liu, Ying Lu, Peng Liu, Yonghong Zhang and Qiuhe Ji

    Version of Record online : 27 MAY 2015, DOI: 10.1111/1756-185X.12648

  20. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia

    International Journal of Rheumatic Diseases

    Volume 17, Issue 6, July 2014, Pages: 679–686, Xinfang Huang, Hui Du, Jieruo Gu, Dongbao Zhao, Lindi Jiang, Xinfu Li, Xiaoxia Zuo, Yi Liu, Zhanguo Li, Xiangpei Li, Ping Zhu, Juan Li, Zhiyi Zhang, Anbin Huang, Yuanchao Zhang and Chunde Bao

    Version of Record online : 28 JAN 2014, DOI: 10.1111/1756-185X.12266